Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY
03:29am, Wednesday, 10'th Dec 2025
Ardsley Advisory Partners LP raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 46.2% during the second quarter, according to the company in its most recent filing with the Securities
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Xeris Biopharma (NASDAQ:XERS)
03:30am, Monday, 08'th Dec 2025
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of “Moderate Buy” from Analysts
01:28am, Monday, 08'th Dec 2025
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock, Marketbeat
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
08:00am, Wednesday, 26'th Nov 2025
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect them
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
02:01pm, Monday, 10'th Nov 2025
ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Dire
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating
01:59pm, Monday, 10'th Nov 2025
ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics an
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
08:06am, Monday, 10'th Nov 2025
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
06:00am, Monday, 10'th Nov 2025
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025
Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may alre
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray) Oral presentation to report results from re
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
08:00am, Monday, 03'rd Nov 2025
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray)
Allspring Global Investments Holdings LLC Sells 74,445 Shares of ARS Pharmaceuticals, Inc. $SPRY
04:22am, Tuesday, 21'st Oct 2025
Allspring Global Investments Holdings LLC lowered its holdings in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 20.2% during the undefined quarter, according to the company in its most recent disclosure
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
08:00am, Wednesday, 08'th Oct 2025
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to bet
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
